Product name: SR-9009
Molecular Formula: C20H24ClN3O4S
Description: SR-9009 is a brand new compound discovered to yield drastically improved performance capabilities in subjects leading to enhanced cardiovascular output and a steady state of exercise leading to improved performance and output that has been well documented. IT is known as an agonist of Rev-ErbA and increases exercise capacity in subjects specifically by increasing mitochondria in skeletal muscle.
||Premium Ceramic Dropper
||1 x Bottle SR-9009 (30ml)
||Premium Research Chemicals
Elite Scientific Analysis:
SR-9009 (Stenabolic) is a brand new compound that can yield drastically improved performance capabilities in subjects through enhanced cardiovascular and metabolic output.
It is an agonist of Rev-ErbA which is a protein that is involved in the regulation of various aspects of food intake, energy expenditure, and sleep.
When SR9009 binds to this protein, increasing its activity, this results in an increase in skeletal muscle mitochondria.
Mitochondria is the powerhouse of the cell and facilitates creation of adenosine triphosphate (ATP) from adenosine diphosphate (ADP). ATP is like food for your muscles at an atomic scale and the more ATP present the more power, strength and endurance a subject will exhibit, muscles cannot contract without using ATP.
As such an increase in skeletal muscle mitochondria also leads to increased fat loss, enhanced endurance and increased exercise capability because there are more cells available to facilitate energy conversion and storage so you can simply do more work.
The subjects resting metabolism is lifted to a higher level meaning that extra energy can be burned even when in a resting state.
This compound also has an impact on circadian rhythm and may have positive impacts on sleeping patterns.
It has been shown to help improve cholesterol levels safely and burn fat and glucose in muscle tissue meaning that it not only helps with weight loss but also with the reduction of cholesterol which can aid in the general health and wellbeing of the cardiovascular system resulting in a stronger heart.
Furthermore, SR9009 decreases pro-inflammatory cytokine IL-6 by over 70%. This means that during inflammation in muscle tissue is significantly reduced meaning a subject will experience less muscle pain associated with damage and can recover more quickly as inflammation is not causing additional issues.
When administered to research subjects this compound was shown to increase their endurance by over 35% and their metabolism was altered such that weight loss continued longer into rest mode than in the control set.
When using this compound a subject would have more energy available to push their body to the limit without experiencing the pain and damage associated with inflammation. They would also have an overall higher metabolic rate meaning that they burn fat faster even when not exercising actively.
SR9009 could also provide additional benefits relating to cholesterol management and cardiovascular health.
There have been no clinical side effects observed in this compound yet. It has no impact on testosterone production and has not exhibited acute toxicity in any organs.
It is currently being considered for medical uses as an exercise replacement for patients who are otherwise unable to carry out exercise and strenuous physical activity.
On the whole SR9009 is an effective compound with the potential to help users surpass their potential and achieve the results they are aiming for. Research on this compound is still ongoing but it has the potential to be useful in a variety of medical areas as a weight loss and obesity treatment and as a treatment to provide additional energy and vitality to people who are not receiving enough naturally.
Solt L., Wang Y., Banerjee S., Hughes T., Kojetin D., Lundasen T., Shin Y., Liu J., Cameron M., Noel R., Yoo S., Takahashi J., Butler A., Kamenecka T., BurrisT., Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists, Nature, 2012, 485(7398), 62–68.
Geldof L., Deventer K., Roels K., Tudela E.,Van Eeno P, In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011, International journal of molecular sciences, 2016, 17(10), 1676.
Amador A., Wang Y., Banerjee S., Kameneka T., Solt L. A., Burris T., Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression, PLoS ONE, 2016, 11(3), e0151014.